HC Wainwright Forecasts Strong Price Appreciation for Insmed (NASDAQ:INSM) Stock

Insmed (NASDAQ:INSM) had its target price boosted by research analysts at HC Wainwright from $90.00 to $120.00 in a report issued on Wednesday,Benzinga reports. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s price objective points to a potential upside of 23.86% from the stock’s previous close. HC Wainwright also issued estimates for Insmed’s FY2028 earnings at $2.63 EPS.

Other research analysts also recently issued research reports about the company. Guggenheim restated a “buy” rating and issued a $101.00 target price on shares of Insmed in a research note on Tuesday, February 25th. Jefferies Financial Group reiterated a “buy” rating on shares of Insmed in a report on Tuesday. Citigroup raised Insmed to a “buy” rating in a research note on Tuesday. UBS Group dropped their price objective on Insmed from $110.00 to $109.00 and set a “buy” rating on the stock in a report on Friday, May 9th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $100.00 price objective on shares of Insmed in a research report on Wednesday, March 19th. One equities research analyst has rated the stock with a sell rating and eighteen have issued a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $104.81.

Insmed Stock Down 1.1%

Insmed stock opened at $96.88 on Wednesday. Insmed has a twelve month low of $60.40 and a twelve month high of $100.00. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37. The firm has a market cap of $17.65 billion, a PE ratio of -17.33 and a beta of 0.80. The firm’s 50 day moving average price is $70.73 and its two-hundred day moving average price is $73.47.

Insmed (NASDAQ:INSM) last posted its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) EPS for the quarter, missing the consensus estimate of ($1.36) by ($0.06). Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. The company had revenue of $92.82 million for the quarter, compared to analysts’ expectations of $91.63 million. During the same quarter in the prior year, the firm earned ($1.06) earnings per share. The company’s revenue was up 22.9% on a year-over-year basis. On average, research analysts predict that Insmed will post -4.56 EPS for the current fiscal year.

Insider Activity at Insmed

In related news, insider Orlov S. Nicole Schaeffer sold 99,172 shares of the business’s stock in a transaction dated Wednesday, June 11th. The stock was sold at an average price of $93.42, for a total transaction of $9,264,648.24. Following the completion of the transaction, the insider now owns 89,407 shares of the company’s stock, valued at approximately $8,352,401.94. The trade was a 52.59% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Michael Alexander Smith sold 1,879 shares of the stock in a transaction that occurred on Thursday, June 5th. The shares were sold at an average price of $73.50, for a total value of $138,106.50. Following the sale, the insider now owns 67,718 shares of the company’s stock, valued at approximately $4,977,273. The trade was a 2.70% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 262,166 shares of company stock worth $20,585,587. 3.00% of the stock is owned by insiders.

Institutional Investors Weigh In On Insmed

Several hedge funds have recently modified their holdings of INSM. Mirae Asset Global Investments Co. Ltd. raised its stake in Insmed by 3.0% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,401 shares of the biopharmaceutical company’s stock valued at $446,000 after purchasing an additional 186 shares during the last quarter. Allspring Global Investments Holdings LLC increased its holdings in shares of Insmed by 8.4% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 423,094 shares of the biopharmaceutical company’s stock worth $29,590,000 after purchasing an additional 32,960 shares during the period. Legato Capital Management LLC increased its holdings in shares of Insmed by 2.2% during the 4th quarter. Legato Capital Management LLC now owns 36,871 shares of the biopharmaceutical company’s stock worth $2,546,000 after purchasing an additional 792 shares during the period. Values First Advisors Inc. raised its position in shares of Insmed by 4.4% during the fourth quarter. Values First Advisors Inc. now owns 5,199 shares of the biopharmaceutical company’s stock valued at $359,000 after buying an additional 221 shares during the last quarter. Finally, V Square Quantitative Management LLC lifted its stake in shares of Insmed by 60.3% in the fourth quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company’s stock valued at $45,000 after buying an additional 248 shares during the period.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.